Sermorelin

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Sermorelin
Systematic (IUPAC) name
L-Tyrosyl-L-alanyl-L-α-aspartyl-L-alanyl-L-isoleucyl-L-phenylalanyl-L-threonyl-L-asparaginyl-L-seryl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucylglycyl-L-glutaminyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutaminyl-L-α-aspartyl-L-isoleucyl-L-methionyl-L-seryl-L-argininamide
Clinical data
Trade names Geref
AHFS/Drugs.com Micromedex Detailed Consumer Information
Pregnancy cat. C (US)
Legal status Discontinued (US)
Routes Injection
Identifiers
CAS number 86168-78-7 YesY
ATC code H01AC04 V04CD03
PubChem CID 16132413
DrugBank DB00010
ChemSpider 17289071 N
UNII 89243S03TE N
KEGG D08509 YesY
ChEMBL CHEMBL1201490 N
Synonyms GRF 1–29
Chemical data
Formula C149H246N44O42S 
Mol. mass 3357.882 g/mol
 N (what is this?)  (verify)

Sermorelin (trade name is Geref) is a growth hormone releasing hormone (GHRH) analogue. It is a 29-amino acid polypeptide representing the 1–29 fragment from endogenous human growth hormone releasing hormone, and is thought to be the shortest fully functional fragment of GHRH.[1] It is used as a test for growth hormone secretion.[2] It is also used as doping substance in sports.[citation needed]

See also[edit]

References[edit]

  1. ^ Prakash A, Goa KL (August 1999). "Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency". BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy 12 (2): 139–57. PMID 18031173. 
  2. ^ Pharmacology (Rang, Dale, Ritter & Moore, ISBN 0-443-07145-4, 5th ed., Churchill Livingstone 2003).